Atypical antipsychotics for mood and anxiety disorders: Safe and effective adjuncts?

Journal of Psychiatry and Neuroscience

Volumn 30, Issue 4, 2005, Pages 232-233

  Blier, Pierre ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADJUVANT THERAPY; ANXIETY DISORDER; BINDING SITE; DEPRESSION; DOPAMINE RELEASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; MOOD DISORDER; MOTOR CONTROL; RECEPTOR BINDING;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; HUMANS; MOOD DISORDERS; TREATMENT OUTCOME;

EID: 24144465700     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Ichikawa J, Kuroki T, Dai J, Meltzer HY. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus. Eur J Pharmacol 1998;351:163-71.
2. Hertel P, Lindblom N, Nomikos GG, Svensson TH. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:815-34.
3. Bergqvist PB, Dong J, Blier P. Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study. Psychopharmacology (Berl) 1999;143:89-96.
4. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73.
5. Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 1997;355:20-9.
6. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
7. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-9.
8. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
9. Canuso C, Gharabawi G, Bouhours P, Leblanc J, Dunbar F, Rapaport MH. Results from open-label phase of ARISe-RD (augmentation with risperidone in resistant depression) [abstract]. Int J Psychopharmacology 2004;7(Suppl 1):S345.
10. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published erratum appears in Arch Gen Psychiatry 2004;61:176]. Arch Gen Psychiatry 2003;60:1079-88.
11. Calabrese JR, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study of quetiapine in bipolar depression [abstract]. Int J Psychopharmacology 2004;7:S330.
12. Dunner DL, Amsterdam JD, Shelton RC, Romano SJ, Loebel A. Adjunctive ziprasidone in treatment-resistant depression: randomized, double-blind, 6-week pilot study [abstract]. Neuropsychopharmacology 2004;29:S99.
13. Corya S, Case M, Briggs S, Tohen M. Olanzapine/fluoxetine combination for treatment-resistant depression with current SSRI failure [abstract]. Int J Psychopharmacology 2004;7(Suppl 1):S162-3.
14. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):12-9.
15. Almeras N, Despres JP, Villeneuve J. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004;65:557-64.
16. Nemeroff CB, Gharabawi GM, Canuso CM, Mahmoud R, Loescher A, Turkoz I, et al. Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial [abstract]. Neuropsychopharmacology 2004;29(Suppl 1):S159.
17. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo controlled study. Int J Neuropsychopharmacol 2003;6:397-401.
18. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005;15:69-74.
19. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004;55:553-5.
20. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004;65:565-8.
21. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-8.
22. Ahearn EP, Krohn A, Connor KM, Davidson JR. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann Clin Psychiatry 2003;15:193-201.